OncoMatch

OncoMatch/Clinical Trials/NCT05842044

NSAID Use After Robotic Partial Nephrectomy

Is NCT05842044 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Ketorolac and Oxycodone for kidney cancer.

Phase 2RecruitingUniversity of MiamiNCT05842044Data as of Jun 2026

Treatment: Ketorolac · Acetaminophen · Oxycodone · Hydromorphone · IbuprofenThe purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

KetorolacAcetaminophenOxycodoneHydromorphoneIbuprofen

Cancer type

Renal Cell Carcinoma

Demographics

Ages ≤ 99

Lab requirements

Kidney function

Glomerular filtration rate (GFR) < 60 mL/min/1.73m2 (Modification of Diet in Renal Disease (MDRD) equation) [excluded]

Cardiac function

Myocardial infarction or unstable angina within 12 months; any history of coronary artery bypass graft surgery [excluded]

Myocardial infarction or unstable angina within 12 months. Any history of coronary artery bypass graft surgery. Glomerular filtration rate (GFR) < 60 mL/min/1.73m2 (Modification of Diet in Renal Disease (MDRD) equation).

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Miami · Miami, Florida

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05842044 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 99 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify